Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 5Neoplasms 5Recurrence 4Renal Insufficiency 3Paraproteinemias 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Blood Protein Disorders 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Cryoglobulinemia, Familial Mixed 1

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × isatuximab × Clear all
NCT02960555 2026-04-15

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
61 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting
63 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡